Report overview
Macular degeneration is a condition in which, macula, a part of the retina, gets damaged or deteriorated. This condition usually affects individuals who are aged 50 years and above and therefore, it is called age-related macular degeneration (AMD). AMD is the leading cause of vision loss and is directly related to the advancement of age. But smoking also plays a vital role in causing AMD. AMD is characterized by the presence of a blurred area near the center of vision that leads to distorted vision. There are two different types of AMD, including dry (atrophic) AMD (dAMD) and wet (neovascular/exudative) AMD (wAMD). The dAMD is the most common type of AMD and accounts for almost 80%-90% of the overall AMD cases.
This report aims to provide a comprehensive presentation of the global market for Gene Therapy for Age-related Macular Degeneration, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Gene Therapy for Age-related Macular Degeneration. This report contains market size and forecasts of Gene Therapy for Age-related Macular Degeneration in global, including the following market information:
Global Gene Therapy for Age-related Macular Degeneration Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Gene Therapy for Age-related Macular Degeneration market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
It has been observed that age-related macular degeneration (AMD) is one of the major causes for vision loss and is characterized by the formation of a blurred area near the center of vision, a condition that mostly affects the geriatric population. According to the CDC, almost 2 million individuals in the US suffer from AMD and by 2050, this number will reach more than 5 million. This will subsequently demand the need for the development of innovative treatments for AMD, driving the market's growth.
We surveyed the Gene Therapy for Age-related Macular Degeneration companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Gene Therapy for Age-related Macular Degeneration Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Gene Therapy for Age-related Macular Degeneration Market Segment Percentages, by Type, 2022 (%)
Subretinal
Intravitreal
Global Gene Therapy for Age-related Macular Degeneration Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Gene Therapy for Age-related Macular Degeneration Market Segment Percentages, by Application, 2022 (%)
Monotherapy
Combination Therapy
Global Gene Therapy for Age-related Macular Degeneration Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Gene Therapy for Age-related Macular Degeneration Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Gene Therapy for Age-related Macular Degeneration revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Gene Therapy for Age-related Macular Degeneration revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
RetroSense Therapeutics
REGENXBIO
AGTC
Outline of Major Chapters:
Chapter 1: Introduces the definition of Gene Therapy for Age-related Macular Degeneration, market overview.
Chapter 2: Global Gene Therapy for Age-related Macular Degeneration market size in revenue.
Chapter 3: Detailed analysis of Gene Therapy for Age-related Macular Degeneration company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Gene Therapy for Age-related Macular Degeneration in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
